These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
146 related articles for article (PubMed ID: 28646958)
1. New tools for malaria control - using them wisely. Greenwood B J Infect; 2017 Jun; 74 Suppl 1():S23-S26. PubMed ID: 28646958 [TBL] [Abstract][Full Text] [Related]
2. Seasonal vaccination against malaria: a potential use for an imperfect malaria vaccine. Greenwood B; Dicko A; Sagara I; Zongo I; Tinto H; Cairns M; Kuepfer I; Milligan P; Ouedraogo JB; Doumbo O; Chandramohan D Malar J; 2017 May; 16(1):182. PubMed ID: 28464937 [TBL] [Abstract][Full Text] [Related]
3. [The RTS,S/AS01 malaria vaccine in children aged 5-17 months at first vaccination]. Vandoolaeghe P; Schuerman L Pan Afr Med J; 2018; 30():142. PubMed ID: 30374388 [TBL] [Abstract][Full Text] [Related]
4. Mass campaigns combining antimalarial drugs and anti-infective vaccines as seasonal interventions for malaria control, elimination and prevention of resurgence: a modelling study. Camponovo F; Ockenhouse CF; Lee C; Penny MA BMC Infect Dis; 2019 Oct; 19(1):920. PubMed ID: 31664924 [TBL] [Abstract][Full Text] [Related]
5. Policy uptake and implementation of the RTS,S/AS01 malaria vaccine in sub-Saharan African countries: status 2 years following the WHO recommendation. Osoro CB; Ochodo E; Kwambai TK; Otieno JA; Were L; Sagam CK; Owino EJ; Kariuki S; Ter Kuile FO; Hill J BMJ Glob Health; 2024 Apr; 9(4):. PubMed ID: 38688566 [TBL] [Abstract][Full Text] [Related]
6. Country specific predictions of the cost-effectiveness of malaria vaccine RTS,S/AS01 in endemic Africa. Galactionova K; Tediosi F; Camponovo F; Smith TA; Gething PW; Penny MA Vaccine; 2017 Jan; 35(1):53-60. PubMed ID: 27890400 [TBL] [Abstract][Full Text] [Related]
7. The RTS,S/AS01 malaria vaccine in children 5 to 17 months of age at first vaccination. Vandoolaeghe P; Schuerman L Expert Rev Vaccines; 2016 Dec; 15(12):1481-1493. PubMed ID: 27841689 [TBL] [Abstract][Full Text] [Related]
8. Malaria in developing countries. López Del Prado GR; Hernán García C; Moreno Cea L; Fernández Espinilla V; Muñoz Moreno MF; Delgado Márquez A; Polo Polo MJ; Andrés García I J Infect Dev Ctries; 2014 Jan; 8(1):1-4. PubMed ID: 24423706 [TBL] [Abstract][Full Text] [Related]
9. The public health impact of malaria vaccine RTS,S in malaria endemic Africa: country-specific predictions using 18 month follow-up Phase III data and simulation models. Penny MA; Galactionova K; Tarantino M; Tanner M; Smith TA BMC Med; 2015 Jul; 13():170. PubMed ID: 26219380 [TBL] [Abstract][Full Text] [Related]
10. Costing RTS,S introduction in Burkina Faso, Ghana, Kenya, Senegal, Tanzania, and Uganda: A generalizable approach drawing on publicly available data. Galactionova K; Bertram M; Lauer J; Tediosi F Vaccine; 2015 Nov; 33(48):6710-8. PubMed ID: 26518406 [TBL] [Abstract][Full Text] [Related]
11. [Malaria vaccines--which vaccines to whom?]. Jepsen S Tidsskr Nor Laegeforen; 2000 May; 120(14):1665-8. PubMed ID: 10901079 [TBL] [Abstract][Full Text] [Related]
12. Human Vaccines and Immunotherapeutics: News. Hum Vaccin Immunother; 2015; 11(6):1298. PubMed ID: 26086584 [No Abstract] [Full Text] [Related]
13. Implementation strategies for the introduction of the RTS,S/AS01 (RTS,S) malaria vaccine in countries with areas of highly seasonal transmission: workshop meeting report. Merle CS; Malar J; 2023 Aug; 22(1):242. PubMed ID: 37612716 [TBL] [Abstract][Full Text] [Related]
14. The time-course of protection of the RTS,S vaccine against malaria infections and clinical disease. Penny MA; Pemberton-Ross P; Smith TA Malar J; 2015 Nov; 14():437. PubMed ID: 26537608 [TBL] [Abstract][Full Text] [Related]
15. Phase 3: RTS,S almost halves malaria cases in young children. Riedmann EM Hum Vaccin Immunother; 2013 Dec; 9(12):2501. PubMed ID: 24716207 [No Abstract] [Full Text] [Related]
16. [The malaria vaccine candidate RTS,S/AS is in phase III clinical trials]. Cohen J; Benns S; Vekemans J; Leach A Ann Pharm Fr; 2010 Nov; 68(6):370-9. PubMed ID: 21073995 [TBL] [Abstract][Full Text] [Related]
17. Fractional Third and Fourth Dose of RTS,S/AS01 Malaria Candidate Vaccine: A Phase 2a Controlled Human Malaria Parasite Infection and Immunogenicity Study. Regules JA; Cicatelli SB; Bennett JW; Paolino KM; Twomey PS; Moon JE; Kathcart AK; Hauns KD; Komisar JL; Qabar AN; Davidson SA; Dutta S; Griffith ME; Magee CD; Wojnarski M; Livezey JR; Kress AT; Waterman PE; Jongert E; Wille-Reece U; Volkmuth W; Emerling D; Robinson WH; Lievens M; Morelle D; Lee CK; Yassin-Rajkumar B; Weltzin R; Cohen J; Paris RM; Waters NC; Birkett AJ; Kaslow DC; Ballou WR; Ockenhouse CF; Vekemans J J Infect Dis; 2016 Sep; 214(5):762-71. PubMed ID: 27296848 [TBL] [Abstract][Full Text] [Related]
18. Current challenges and proposed solutions to the effective implementation of the RTS, S/AS01 Malaria Vaccine Program in sub-Saharan Africa: A systematic review. Dimala CA; Kika BT; Kadia BM; Blencowe H PLoS One; 2018; 13(12):e0209744. PubMed ID: 30596732 [TBL] [Abstract][Full Text] [Related]
19. Malaria vaccination in Africa: A mini-review of challenges and opportunities. Olawade DB; Wada OZ; Ezeagu CN; Aderinto N; Balogun MA; Asaolu FT; David-Olawade AC Medicine (Baltimore); 2024 Jun; 103(24):e38565. PubMed ID: 38875411 [TBL] [Abstract][Full Text] [Related]
20. The biological function of antibodies induced by the RTS,S/AS01 malaria vaccine candidate is determined by their fine specificity. Chaudhury S; Ockenhouse CF; Regules JA; Dutta S; Wallqvist A; Jongert E; Waters NC; Lemiale F; Bergmann-Leitner E Malar J; 2016 May; 15():301. PubMed ID: 27245446 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]